"We can use this technology to extract highly relevant information from tumors that may guide future treatment choices or foster the development of new therapies."– Levi Garraway, MD, PhDCo-developer of OncoMap
At the heart of the new genetic screening research program at Dana-Farber and Brigham and Women's Hospital is OncoMap, a system that scans patients' tumor tissue for gene mutations involved in cancer. Information generated by OncoMap will provide a treasury of data for research into the genetic connection between tumors and their response to therapy.
Developed by scientists at Dana-Farber and the Broad Institute of MIT and Harvard, OncoMap is able to scan large numbers of tumor samples at a reasonable cost – a key prerequisite for a research project open to as many patients as wish to participate. The system is taking its place alongside the pathologist's microscope as a tool for categorizing cancers and investigating novel treatments.
Paths of Progress Fall/Winter 2011 Table of Contents
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: